TherapeuticsMD

Bespreek hier de kleinere aandelen van de beurs in New York

Gebruikersavatar
Lama Daila
Forum veteraan
Forum veteraan
Berichten: 1818
Lid geworden op: 20 Jul 2017 10:53
waarderingen: 3176
Contact:

TherapeuticsMD

Berichtdoor Lama Daila » 24 Jul 2018 19:37

https://www.therapeuticsmd.com/

Corporate Presentation: https://ir.therapeuticsmd.com/static-fi ... 6ca84f3fc4

8FE318CD-51BE-4F8C-82A5-13D1480CADAE.jpeg


About Us:

Optimizing health is our goal.
Empowering her is our purpose.

TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their healthcare issues. We create products to address the unique changes and challenges women experience through every stage of their lives.
With momentum fueled by the needs of our customers, we combine entrepreneurial spirit and clinical expertise to develop innovative solutions designed to go beyond what is presently available. This includes a variety of therapies in our pipeline, along with prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands.
We listen to women. And to the professionals who treat them.
From pregnancy to menopause, we believe the only way to truly connect with and understand women and their healthcare professionals is to ask questions. Through national surveys and studies, we ask women about their healthcare concerns and current available treatments. We take their insights and turn them into strategies for crafting better solutions for her, for life.
Our dedication to bettering the lives of women, no matter their age or stage of life, is our main focus every single day. But we know we cannot do that alone. So we depend on our partnerships with other dedicated organizations, associations, and advocacy groups to support us as we create innovative solutions for women.
U kunt de afbeeldingen in deze bijlage niet bekijken, registreer hier en bekijk de bijlage.
uynod liked last!
https://twitter.com/lama_daila



powered by Surfing Waves

Gebruikersavatar
Lama Daila
Forum veteraan
Forum veteraan
Berichten: 1818
Lid geworden op: 20 Jul 2017 10:53
waarderingen: 3176
Contact:

Re: TherapeuticsMD

Berichtdoor Lama Daila » 24 Jul 2018 19:57

Resultaten fase 3 voor TX-001HR (= Replenish Trial) zijn in juni bekend gemaakt.
FDA-goedkeuring verwacht op 28 oktober.

B785379A-9825-447F-92C2-9056A108DF22.jpeg
U kunt de afbeeldingen in deze bijlage niet bekijken, registreer hier en bekijk de bijlage.
https://twitter.com/lama_daila

Gebruikersavatar
Lama Daila
Forum veteraan
Forum veteraan
Berichten: 1818
Lid geworden op: 20 Jul 2017 10:53
waarderingen: 3176
Contact:

Re: TherapeuticsMD

Berichtdoor Lama Daila » 24 Jul 2018 20:00

From Yahoo-forum:
“During their July 14 Goldman Sachs Conference presentation, the CEO mentioned the company was working on global partnership. He expected the announcement would come within 4-6 weeks (by July 26). He said partnership for Europe will come after 001 is launched.“
lode78 liked last!
https://twitter.com/lama_daila

lode78
Forum actieveling
Forum actieveling
Berichten: 297
Lid geworden op: 03 Feb 2018 22:22
waarderingen: 69
Contact:

Re: TherapeuticsMD

Berichtdoor lode78 » 24 Jul 2018 20:22

beste Lama...
het aandeel heeft tussen begin 2011 tot heden ni veel gepresteerd....
met de fase 3 zou nu de ommegang zijn ingezet na 7 jaar?...
kende het aandeel niet en als u zegt intressant ben ik zeer geneigd u te geloven.
Lampi liked last!

Lampi
Forum actieveling
Forum actieveling
Berichten: 568
Lid geworden op: 21 Jun 2017 19:29
waarderingen: 191
Contact:

Re: TherapeuticsMD

Berichtdoor Lampi » 24 Jul 2018 20:23

Thx vr de tip! Net ff ingelezen..kan bijna niet fout lopen..beperkt in met 500 stuks aan 6,55...ns zien wat de komende maanden doen en eventueel op/afbouwen :up:
lode78 liked last!

Gebruikersavatar
Lama Daila
Forum veteraan
Forum veteraan
Berichten: 1818
Lid geworden op: 20 Jul 2017 10:53
waarderingen: 3176
Contact:

Re: TherapeuticsMD

Berichtdoor Lama Daila » 24 Jul 2018 20:28

Koersdoelen van analisten: onlangs nog 11 USD en 12 USD.
Hier het overzicht vanuit Bolero (ik weet niet of alle koersdoelen nog actueel zijn):
D7A12689-04ED-480B-A6FB-9CE94A775974.jpeg
U kunt de afbeeldingen in deze bijlage niet bekijken, registreer hier en bekijk de bijlage.
lode78 liked last!
https://twitter.com/lama_daila

Gebruikersavatar
Lama Daila
Forum veteraan
Forum veteraan
Berichten: 1818
Lid geworden op: 20 Jul 2017 10:53
waarderingen: 3176
Contact:

Re: TherapeuticsMD

Berichtdoor Lama Daila » 24 Jul 2018 20:33

https://www.smarteranalyst.com/analyst- ... s-imvexxy/

EE0B7AD7-3A81-4BC0-BDFF-90FC7EC4017A.png
U kunt de afbeeldingen in deze bijlage niet bekijken, registreer hier en bekijk de bijlage.
lode78 liked last!
https://twitter.com/lama_daila

lode78
Forum actieveling
Forum actieveling
Berichten: 297
Lid geworden op: 03 Feb 2018 22:22
waarderingen: 69
Contact:

Re: TherapeuticsMD

Berichtdoor lode78 » 24 Jul 2018 20:39

een gemiddeld koersdoel van 16 zoiets...500 maal kleine 10 euro...nice :D
zie mijzelf ook wel een 300 stuks kopen maar probiodrug en acacia zitten ook op mijn watchlist...
effe bekijken!
fijne avond lama

Gebruikersavatar
Lama Daila
Forum veteraan
Forum veteraan
Berichten: 1818
Lid geworden op: 20 Jul 2017 10:53
waarderingen: 3176
Contact:

Re: TherapeuticsMD

Berichtdoor Lama Daila » 24 Jul 2018 20:41

https://www.smarteranalyst.com/analyst- ... ock-heres/

Cantor Sees 280% Upside for TherapeuticsMD (TXMD) Stock; Here’s Why

Now that TXMD has disproved the bears with a key victory for Imvexxy, Cantor's William Tanner angles for another win come October for TX-001.

Julie Lamb-May 30, 2018, 10:06 AM EDTSHARE ON:
TherapeuticsMD (NASDAQ:TXMD) investors are celebrating the FDA’s green light for its vaginal treatment Imvexxy, a drug designed as an applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia).

For context, dyspareunia is a symptom of vulgar and vaginal atrophy (VVA), a symptom stemming from menopause. Notably, TXMD’s Imvexxy is the sole product in its therapeutic class that offers a 4mcg as well as a 10mcg dose, with the former dose posing forth the lowest approved dose of vaginal estradiol on the market. In reaction to the bullish victory, shares have been sent racing almost 6% this morning.

Cantor analyst William Tanner cheers “when the improbable becomes a reality.” Moreover, the analyst notes that details of the 4mcg and 10mcg dose launches along with a label carrying the estrogen class black box warning all seem to have been prematurely posted a week ago.

On the heels of the approval, the analyst reiterates an Overweight rating on TXMD stock with a $26 price target, which implies a 282% upside from current levels. (To watch Tanner’s track record, click here)

The win “sets the company on a course to bring two important therapies to the market for treating symptoms associated with menopause, in our opinion. With the approval, TXMD can access $75 million from the recently-struck loan agreement. The PDUFA date for TX-001, an investigational drug for treating vasomotor symptoms (VMS, aka, hot flushes) of menopause is October 28. If approved, 2018 should be regarded as the most important year in the company’s history, in our view,” asserts Tanner, who says to put it bluntly there is “nothing not to like” here.

“Given the drug’s review history and apparent market skepticism as to its approvability (e.g., the share valuation), the FDA’s decision should be viewed as a major event,” wagers Tanner, who highlights: “Approval of the two doses supports the notion that they are effective and we believe they foot well with the treatment recommendation of using the lowest effective dose. Perhaps taken up at a later date could be modification of the black box warning but we question whether the FDA was prepared to broach that subject now […]”

However, could prospective TX-001 approval “steal spotlight” from the triumph of Imvexxy’s launch? After all, bears can no longer trumpet the skeptical question of an FDA win here, and Tanner anticipates investors that remain bearish on TXMD may deem the launch of the asset underwhelming. Tanner’s bet: a win on TX-001 come October 28th, especially considering its bigger revenue prospects may eclipse just how “robustly” the Imvexxy launch transpires.

Bottom line, the expectations for Imvexxy do not seem to trip TXMD up for “failure” ahead. For this year, the analyst calls for $18.5 million in revenue, hitting $128 million by next year, against FactSet consensus calling for $21 million in 2018 and $160 million by 2019. Tanner projects Imvexxy can magnetize roughly 4,000 yearly VVA patients this year (out of around 2.6 million yearly) and around 130,000 by next year.

TipRanks indicates a strong bullish camp betting on TXMD stock. All 4 analysts polled in the last 3 months rate a Buy on TXMD stock. With a return potential of 133%, the stock’s consensus target price stands at $15.00.
lode78 liked last!
https://twitter.com/lama_daila

Lampi
Forum actieveling
Forum actieveling
Berichten: 568
Lid geworden op: 21 Jun 2017 19:29
waarderingen: 191
Contact:

Re: TherapeuticsMD

Berichtdoor Lampi » 24 Jul 2018 22:16


Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. 
Registreer binnen enkele tellen